Fig. 3
Outcomes of patients with and without persisting mutations in remission. a RFS and b OS for patients with and without persisting mutations in the remission sample. c CIR, with alloSCT or death in first CR/CRi treated as competing events, for patients with and without persisting mutations. d CIR after alloSCT in first CR/CRi
